Lookin’ for Growth in All the Global Places
How to invest internationally, if going across borders makes sense for your portfolio.
Charles Rotblut
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Commentary & Analysis
Is Roche Holding AG (ADR) (RHHBY) Stock a Good Investment?
Learn more about Roche Holding AG (ADR)'s (RHHBY) stock grades for Value, Momentum and Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | RHHBY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $345,920.1 | $569.9 | 99% |
|
| Shares Out (Mil) | 998.8 | 44.8 | 94% |
|
| Institutional Ownership | 17.9% | 84.6% | 10% |
|
| Float (Mil) | 654.1 | 45.1 | 88% |
|
| Beta | 0.34 | 0.67 | 19% |
|
| Avg Daily Volume (000s) | 2,320 | 294 | 85% |
|
| Price Change (52-week) |
37.1% | 65.2% | 74% |
|
| Growth | RHHBY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.2% | 6.7% | 28% |
|
| Net Income (5yr) | 0.1% | (2.0%) | 40% |
|
| EPS (5yr) | 1.6% | 14.9% | 33 |
|
| Dividends (5yr) | 3.7% | 0.0% | 99% |
|
| Cash Flow (5yr) | (33.7%) | (14.9%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RHHBY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $77,920 | $230 | 98% |
|
| Net Income (TTM) (Mil) | $15,274 | ($11) | 99% |
|
| EPS (TTM) | $19.188 | ($0.600) | 98% |
|
| Operating Cash Flow (TTM) (Mil) | $23,994 | ($6) | 99% |
|
| Net Cash Flow (TTM) (Mil) | ($2,647) | $4 | 1% |
|
| Long-Term Debt (Q1) (Mil) | $33,076 | $7 | 97% |
|
| Enterprise Value (Q1) (Mil) | $397,692 | $493 | 99% |
|
| Valuation | RHHBY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.89 | na |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RHHBY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 74.2% | 65.9% | 85% |
|
| Net Margin | 19.6% | (0.2%) | 79% |
|
| ROA | 12.7% | (25.5%) | 91% |
|
| ROE | 39.9% | (21.4%) | 91% |
|
| Liabilities to Assets | 62.6% | 35.5% | 57% |
|
| F-Score | na | 3 | na |
|
Roche Holding AG did not pass any screens on 7/30/2026.
